 |
|
New research may show why some prostate cancer recurs after treatment
October 12, 2007Cancer researchers have long worked to understand why some prostate cancers recur after the use of therapies designed to stop the production of testosterone and other androgens that fuel cancer cell growth. New research has now detected that androgen-synthesizing proteins are present within cancer cells, which suggests that cancer cells may develop the capacity to produce their own androgens.
The presence of these proteins may explain why some prostate cancers become resistant to these widely-used therapies, and offers new directions for research into future treatments that could block the development of androgens in the cancer cells. The study, funded by the Prostate Cancer Foundation and the National Cancer Institute, was presented today at the Foundation's annual Scientific Retreat.
Androgen-deprivation therapy is routinely used in the treatment of advanced (metastatic) prostate cancer, in order to deprive cancer cells of these hormones that fuel their growth. However, over time cancer cells can become "androgen independent," and grow even in the presence of these medications. This type of the cancer is a lethal form of the disease, with most patients dying 18 to 24 months after becoming resistant to hormone suppression. Research in the field has focused on understanding the mechanisms used by these cancer cells to become "castration resistant".
Investigators Peter Nelson, M.D., Elahe Mostaghel, M.D., Ph.D., and Bruce Montgomery, M.D. from the Fred Hutchinson Cancer Research Center and University of Washington, conducted tests on tumors removed and preserved from deceased prostate cancer patients during "rapid autopsies" immediately after death. All the patients had received androgen-blocking therapies during the course of treatment to suppress tumor growth.
The researchers were able to detect in the tumors the key proteins, or enzymes, needed for a cell to produce its own testosterone from cholesterol present in the cell. "This study, along with other research in the field, suggests that cancer cells may have the ability to adapt and produce their own androgens that permit these cancer cells to survive," explained Nelson. "While this study does not prove that the cancer cells act in this way, it does show it is possible."
The work of Nelson and Montgomery was inspired, they say, by the work of Jack Geller in the 1980's, which demonstrated that testosterone and potent metabolites could still be found in prostate tumors at levels exceeding those found in the blood, which suggested the cancer could develop its own testosterone. Recent research by Jim Mohler, M.D., Stephanie Page, M.D., Ph.D., and other investigators has also revisited these ideas. "In other studies, men without prostate cancer who received androgen-suppressing drugs also showed surprisingly high levels of androgen in their prostates even with low levels in their blood," noted Nelson, "and biopsies of the prostate following testosterone suppression in men who have prostate cancer have shown similar results."
The research by the Hutchinson Center/University of Washington team now offers a plausible explanation and mechanism of action for these findings. In the study, researchers removed entire metastases, or tumors, from deceased prostate cancer patients who had agreed to be part of a "rapid autopsy" research program. At least three tumors were removed from each patient, and examined for androgen levels and the presence of the enzymes responsible for androgen metabolism.
Nelson noted that the study offers directions for future research in this area. "The next phase will be to determine the source of androgen precursors. These are likely to be derived from andrenal androgens, or possibly from cholesterol. A key experiment will be to follow these precursor molecules in the cancer cells to see if they are converted to testosterone," said Nelson, "hence proving these tumor cells are actually capable of such a conversion."
New medications are being tested in the early stages of clinical trials with the goals of blocking androgen synthesis. Abiraterone, for example, seeks to inhibit the enzymes in the metabolic pathways that convert cholesterol to androgens, and work by blocking androgen synthesis in both the adrenal gland and possibly in the tumors themselves. Other classes of drugs being tested attempt to more completely block interactions with the receptor for androgens within the tumor cells, or alter the degradation of androgens. Rather than continuous treatment which is associated with side-effects, a strategy of maximally inhibiting the androgen axis for a short-time or on an intermittent basis could have the effect of destroying or suppressing cancer cell growth for long time periods. Investigators leading these trials also discussed initial findings in the session at PCF's annual Scientific Retreat.
Nelson lauded the Prostate Cancer Foundation for their leadership role in funding research in the field. "What PCF has allowed is exploration of innovative and high risk ideas, instrumental in allowing us to pursue this area of investigation," emphasized Nelson.
GYMR
Investigators Peter Nelson, M.D., Elahe Mostaghel, M.D., Ph.D., and Bruce Montgomery, M.D. from the Fred Hutchinson Cancer Research Center and University of Washington, conducted tests on tumors removed and preserved from deceased prostate cancer patients during "rapid autopsies" immediately after death. All the patients had received androgen-blocking therapies during the course of treatment to suppress tumor growth.
The researchers were able to detect in the tumors the key proteins, or enzymes, needed for a cell to produce its own testosterone from cholesterol present in the cell. "This study, along with other research in the field, suggests that cancer cells may have the ability to adapt and produce their own androgens that permit these cancer cells to survive," explained Nelson. "While this study does not prove that the cancer cells act in this way, it does show it is possible."
The work of Nelson and Montgomery was inspired, they say, by the work of Jack Geller in the 1980's, which demonstrated that testosterone and potent metabolites could still be found in prostate tumors at levels exceeding those found in the blood, which suggested the cancer could develop its own testosterone. Recent research by Jim Mohler, M.D., Stephanie Page, M.D., Ph.D., and other investigators has also revisited these ideas. "In other studies, men without prostate cancer who received androgen-suppressing drugs also showed surprisingly high levels of androgen in their prostates even with low levels in their blood," noted Nelson, "and biopsies of the prostate following testosterone suppression in men who have prostate cancer have shown similar results."
The research by the Hutchinson Center/University of Washington team now offers a plausible explanation and mechanism of action for these findings. In the study, researchers removed entire metastases, or tumors, from deceased prostate cancer patients who had agreed to be part of a "rapid autopsy" research program. At least three tumors were removed from each patient, and examined for androgen levels and the presence of the enzymes responsible for androgen metabolism.
Nelson noted that the study offers directions for future research in this area. "The next phase will be to determine the source of androgen precursors. These are likely to be derived from andrenal androgens, or possibly from cholesterol. A key experiment will be to follow these precursor molecules in the cancer cells to see if they are converted to testosterone," said Nelson, "hence proving these tumor cells are actually capable of such a conversion."
New medications are being tested in the early stages of clinical trials with the goals of blocking androgen synthesis. Abiraterone, for example, seeks to inhibit the enzymes in the metabolic pathways that convert cholesterol to androgens, and work by blocking androgen synthesis in both the adrenal gland and possibly in the tumors themselves. Other classes of drugs being tested attempt to more completely block interactions with the receptor for androgens within the tumor cells, or alter the degradation of androgens. Rather than continuous treatment which is associated with side-effects, a strategy of maximally inhibiting the androgen axis for a short-time or on an intermittent basis could have the effect of destroying or suppressing cancer cell growth for long time periods. Investigators leading these trials also discussed initial findings in the session at PCF's annual Scientific Retreat.
Nelson lauded the Prostate Cancer Foundation for their leadership role in funding research in the field. "What PCF has allowed is exploration of innovative and high risk ideas, instrumental in allowing us to pursue this area of investigation," emphasized Nelson.
GYMR
Prostate Cancer Current Events and Prostate Cancer News RSSRelationship between prostate information and lower urinary-tract symptoms evident
In the December issue of European Urology (http://www.elsevier.com/locate/eururo) Dr. Curtis Nickel and associates report on the evidence of a relationship between prostate inflammation and lower urinary tract symptoms (LUTS) in men enrolled in the REDUCE trial.
A card-swipe for medical tests
University of Utah scientists successfully created a sensitive prototype device that could test for dozens or even hundreds of diseases simultaneously by acting like a credit card-swipe machine to scan a card loaded with microscopic blood, saliva or urine samples.
Media coverage of lung cancer is increasing, and increasingly negative, new report shows
CancerCare today announced that despite an overall increase in news reporting on lung cancer, the overall tone of lung cancer media coverage has become significantly more negative.
Supercomputer provides massive computational boost to biomedical research at TGen
In less time than the blink of an eye, the Translational Genomics Research Institute's new supercomputer at Arizona State University can do operations equal to every dollar in the recent Wall Street bailout.
Prostate cancer gene test provides new early detection
Prostate cancer (PCa) is one of the most common male cancers in the Western world. Currently, early detection of PCa depends on an abnormal digital rectal examination and an elevated prostate-specific-antigen (PSA) level requiring a prostate biopsy, often associated with anxiety, discomfort, complications, and heavy expenses.
New Catheter-less Technique May Ease the Pain and Discomfort of Prostate Cancer Recovery
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter.
Racial disparities decline for cancer in Missouri
Cancer death rates in the United States are highest among African Americans, but a new report shows that in Missouri the disparity in cancer incidence and death between African Americans and whites is declining.
OHSU Cancer Institute researchers study breathing during radiation
Oregon Health & Science University researchers have determined exactly how much breathing affects prostate movement during radiation treatment.
Hormone therapy before radiation seed implants for prostate cancer
Men over 70 years of age with early-stage prostate cancer have 20 percent higher mortality if they are treated first with hormone therapy before being treated with radiation seed implants (brachytherapy), compared to men who are treated with brachytherapy alone.
Newly found gene variants account for kidney diseases among African-Americans
For the first time, researchers have identified variations in a single gene that are strongly associated with kidney diseases disproportionately affecting African-Americans. This work was conducted by researchers at the National Institutes of Health (NIH) and by NIH-funded investigators at the Johns Hopkins University.
More Prostate Cancer Current Events and Prostate Cancer News Articles
 | Dr. Patrick Walsh's Guide to Surviving Prostate Cancer, Second Edition by Patrick C. Walsh, Janet Farrar Worthington EVERY MAN NEEDS THIS BOOK! Each year, more than 200,00 American men are diagnosed with prostate cancer. The good news is that more men are being cured of this disease than ever before. Now in a revised second edition, this lifesaving guide by Dr. Patrick Walsh and ard-winning science writer Janet Farrar Worthington offers a message of hope to every man facing this illness. Prostate cancer is... |
 | A Primer on Prostate Cancer: The Empowered Patient's Guide by Stephen Strum, Donna L. Pogliano ¡§A Primer on Prostate Cancer, The Empowered Patient¡¦s Guide¡¨ is a basic resource to be used by patients and physicians when there has been a diagnosis of prostate cancer. It outlines a strategy of disease management that is designed to maximize outcomes for the patient and his loved ones. All aspects of diagnosis and testing are discussed; all currently approved treatments for prostate... |
 | Eat to Beat Prostate Cancer Cookbook by David Ricketts Prostate cancer is now the most common nonskin cancer among men in the United States. In 2005 alone, 250,000 new cases were diagnosed, and that number is certain to rise with each passing year. No one is more aware of this than David Ricketts, experienced cookbook author and recent prostate cancer survivor.Shortly after surgery and radiation treatments, Ricketts began to research food and... |
 | Surviving Prostate Cancer Without Surgery by Bradley Hennenfent The niche bestseller "Surviving Prostate Cancer Without Surgery" begins with the shooting of a urologist and includes a World War II Battle. The book exposes the big lie about radical prostate surgery, is filled with cartoons and simple diagrams, and is written for the average layperson in easy-to-understand style. "Surviving Prostate Cancer Without Surgery" quotes Dr. Gary Onik, M.D.,... |
 | You Can Beat Prostate Cancer by Robert J. Marckini The task of choosing the right prostate cancer treatment is daunting. It is further complicated by conflicting information the patient receives from physicians and the Internet. This book is written by a prostate cancer survivor who now runs an international prostate cancer support group. It's about his journey and the important things he learned along the way. It is the book the author wishes... |
 | The Prostate Cancer Treatment Book by Peter Grimm, John Blasko, John Sylvester The latest and most progressive treatment advice from prostate cancer experts at the nation's top medical centers For each of the nearly 200,000 Americans diagnosed with prostate cancer annually, the months following the diagnosis are a time of momentous decisions and enormous emotional strain. This book offers readers complete answers to all their questions about the best treatment options for... |
 | Prostate And Cancer: A Family Guide To Diagnosis, Treatment And Survival (3rd Edition) by Sheldon Marks Prostate cancer has become the most-diagnosed cancer in America and the second leading killer of men. Sadly, more than 189,000 men will be diagnosed with the disease in 2002. Dr. Sheldon Marks, a specialist in the diagnosis and treatment of prostate cancer, is the authority that many have come to depend on-both in his practice and through his book, Prostate and Cancer-when cancer has posed a... |
 | Surviving Prostate Cancer without Surgery: The New Gold Standard Treatment That Can Save Your Life and Lifestyle by Michael J. Dattoli, Jennifer Cash, Don Kaltenbach Unlike any other book on the subject, Surviving Prostate Cancer Without Surgery provides the most up-to-date information and lifesaving advice from three essential points of view -- physician, nurse, and patient-survivor. Three leading cancer care specialists guide readers step by step through diagnosis, treatment and recovery, covering both the physical and emotional challenges of the disease. ... |
 | Surviving Prostate Cancer: What You Need to Know to Make Informed Decisions (Yale University Press Health & Wellness) by E. Fuller Torrey When Dr. E. Fuller Torrey was diagnosed with prostate cancer, none of the books he could find was current enough or comprehensive enough to satisfy his need for information. This book is for the hundreds of thousands of other men who each year receive the same frightening diagnosis. It is the book Dr. Torrey wished he had when he was facing the countless questions that a man with prostate cancer,... |
 | PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience by Fuller Jones Proton Beam Therapy is an advanced cancer treatment based on the elegant physics of the proton. It is not well known, because there are currently only five hospitals in the U.S. that have the expensive and complex equipment to administer it. Protons have been used for cancer treatment in the U. S. since 1990 with success comparable to all other options, but with minimal side effects. Proton... |
| © 2008 BrightSurf.com |